Sonoma Pharmaceuticals Stock Revenue
| SNOA Stock | USD 2.93 0.08 2.81% |
Sonoma Pharmaceuticals fundamentals help investors to digest information that contributes to Sonoma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Sonoma Stock. The fundamental analysis module provides a way to measure Sonoma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sonoma Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 12.7 M | 11.3 M |
Sonoma | Revenue |
Sonoma Pharmaceuticals Company Revenue Analysis
Sonoma Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Sonoma Pharmaceuticals Revenue | 12.73 M |
Most of Sonoma Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sonoma Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Sonoma
Projected quarterly revenue analysis of Sonoma Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Sonoma Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Sonoma Pharmaceuticals' stock price.
Sonoma Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Sonoma Pharmaceuticals is extremely important. It helps to project a fair market value of Sonoma Stock properly, considering its historical fundamentals such as Revenue. Since Sonoma Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sonoma Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sonoma Pharmaceuticals' interrelated accounts and indicators.
| -0.37 | -0.71 | 0.23 | 0.74 | 0.31 | ||
| -0.37 | 0.82 | -0.8 | -0.5 | -0.29 | ||
| -0.71 | 0.82 | -0.64 | -0.84 | -0.24 | ||
| 0.23 | -0.8 | -0.64 | 0.57 | 0.43 | ||
| 0.74 | -0.5 | -0.84 | 0.57 | 0.3 | ||
| 0.31 | -0.29 | -0.24 | 0.43 | 0.3 |
Click cells to compare fundamentals
Sonoma Revenue Historical Pattern
Today, most investors in Sonoma Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sonoma Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sonoma Pharmaceuticals revenue as a starting point in their analysis.
Sonoma Pharmaceuticals Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Sonoma Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Sonoma Pharmaceuticals reported 12.73 M of revenue. This is 99.83% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 99.87% higher than that of the company.
Sonoma Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sonoma Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sonoma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Sonoma Pharmaceuticals by comparing valuation metrics of similar companies.Sonoma Pharmaceuticals is currently under evaluation in revenue category among its peers.
Sonoma Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sonoma Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sonoma Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Sonoma Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Sonoma Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sonoma Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sonoma Pharmaceuticals' value.| Shares | Citigroup Inc | 2024-09-30 | 180 | Bank Of America Corp | 2024-06-30 | 172 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 86.0 | Wells Fargo & Co | 2024-06-30 | 33.0 | Hanson Mcclain Inc | 2024-09-30 | 3.0 | Hbc Financial Services, Pllc | 2024-06-30 | 2.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Jane Street Group Llc | 2024-06-30 | 45.3 K | State Street Corp | 2024-06-30 | 24.3 K |
Sonoma Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.35) % | ||||
| Current Valuation | 89.77 K | ||||
| Shares Outstanding | 1.34 M | ||||
| Shares Owned By Insiders | 1.50 % | ||||
| Shares Owned By Institutions | 2.41 % | ||||
| Number Of Shares Shorted | 54.67 K | ||||
| Price To Earning | 2.57 X | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 0.31 X | ||||
| Revenue | 12.73 M | ||||
| Gross Profit | 4.48 M | ||||
| EBITDA | (4.53 M) | ||||
| Net Income | (4.83 M) | ||||
| Cash And Equivalents | 5.59 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 608 K | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 3.05 X | ||||
| Book Value Per Share | 7.86 X | ||||
| Cash Flow From Operations | (2.4 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (0.99) X | ||||
| Target Price | 19.5 | ||||
| Number Of Employees | 10 | ||||
| Beta | 1.38 | ||||
| Market Capitalization | 3.92 M | ||||
| Total Asset | 14.74 M | ||||
| Retained Earnings | (194.35 M) | ||||
| Working Capital | 8.83 M | ||||
| Current Asset | 12.89 M | ||||
| Current Liabilities | 3.55 M | ||||
| Net Asset | 14.74 M |
About Sonoma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sonoma Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sonoma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sonoma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out Sonoma Pharmaceuticals Piotroski F Score and Sonoma Pharmaceuticals Altman Z Score analysis. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 20.967 | Quarterly Revenue Growth (0.01) | Return On Assets (0.20) | Return On Equity (0.75) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.